Anaphylaxis, Hypersensitivity
Conditions
Keywords
Immunotherapy, Epinephrine, Upper airway laryngeal edema, Upper airway pharyngeal edema, Hypersensitivity, Hypersensitivity, immediate, Anaphylaxis, Vasoconstrictor agents, Adrenergic alpha-Agonists, Adrenergic beta-Agonists, Bronchodilator agents
Brief summary
The purpose of this exploratory study is to evaluate the effects of inhaled epinephrine in patients with known or suspected metabisulfite sensitivity who experience a systemic allergic reaction (SAR) while undergoing allergy testing, immunotherapy or oral challenges.
Detailed description
This is a Phase 1b, single-center, open label exploratory study that will evaluate the effects of inhaled epinephrine in patients with known or suspected metabisulfite sensitivity and who are undergoing planned allergy testing, subcutaneous immunotherapy (SCIT), oral challenges (food and/or drug), or oral immunotherapy (OIT). This study will enroll and dose up to 60 patients. The maximum duration of subject participation is approximately 1 week.
Interventions
0.125 mg per inhalation. The maximum proposed dose to be administered is 1.0 mg (consisting of 8 inhalations of 0.125 mg over 6 minutes).
Sponsors
Dr. George Luciuk
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Males or females, aged ≥ 18 years with known or suspected metabisulfite sensitivity who can also have a clinical history of immunoglobulin E (IgE)-mediated allergy, including a documented sensitivity to allergens (i.e., positive skin prick test, or positive in vitro serum IgE). 2. Have undergone either a) allergy testing for suspected sensitivity/allergy, b) oral challenge (food and/or drug), c) oral immunotherapy (OIT) to treat existing allergies or d) subcutaneous immunotherapy (SCIT) following a prior allergic reaction AND experiences a systemic allergic reaction (SAR) rated as Grade ≥2, following allergy testing, SCIT, oral challenge (food and/or drug), or OIT, and deemed eligible for enrollment by the Principal Investigator. 3. For females of child-bearing potential, not pregnant or lactating, willing to use a highly effective method of birth control between Screening and End-of-Study Visits.
Exclusion criteria
1. Known reaction or sensitivity to epinephrine or any of the ingredients of inhaled epinephrine. 2. Known history or presence of clinically relevant cardiovascular, respiratory, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurological, psychological or other disease/condition that could confound the results of the study or place the subject at undue or additional risk per the judgment of the Investigator. 3. Uncontrolled asthma or chronic obstructive pulmonary disease (COPD). 4. Recent life-threatening asthma within the last 6 months which required admission to hospital prior to study start. 5. Use of any tobacco or of any inhaled products, including vaping and water pipes (Hookahs) within 12 months prior to screening and/or a 10 pack per year history of use. 6. Use of antihistamines within 5 days and/or bronchodilators within 24 hours of pre-challenge visit. 7. Surgical procedures within 90 days of screening that could result in confounding of results or additional risk to the subject, per the judgment of the Investigator. 8. Abnormal vital signs at screening (i.e., systolic blood pressure: \< 90 or \>140 mmHg, diastolic blood pressure: \< 40 or \> 90 mmHg or, Heart rate: \< 45 or \> 100 bpm), respiration rate \< 8 or \> 20 resp./min. 9. Females who are pregnant, plan to become pregnant or lactating. 10. Participation in another clinical study involving an investigational drug within 30 days prior to screening, an investigational biologic within 60 days prior to screening, or current/planned participation in another interventional study during this study. 11. Previous treatment in this study. 12. Any other reason that, in the opinion of the Investigator, is likely to unfavourably alter subject risk-benefit, confound results, or make it difficult for the subject to fully comply with study requirements.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to resolution of systemic symptoms. | From first dose administration to 60 minutes following first dose administration. | Defined as a reduction in systemic allergic reaction (SAR) Grade to ≤ 1. |
Countries
Canada
Outcome results
None listed